Device industry experience, world-class physiology.
Ceryx combines a leadership team drawn from the medical device and investment industries with the scientists who discovered the therapy.
Executive team
Dr Stuart Plant
PhD in biomedical engineering. Formerly GE HealthCare, then eight years at IP Group, where he backed Ceryx as an investor before becoming its founding permanent CEO.
LinkedIn
Malcolm Hamer
Electronics and firmware engineer with 20 years’ analogue and digital design experience, including eight years at LifeScan developing Bluetooth-connected blood glucose monitors.
LinkedIn
Prof. Zaheer Yousef OBE
Consultant cardiologist at the University Hospital of Wales, honorary chair at Cardiff University and Clinical Lead for Cardiovascular Research in Wales. Chief Investigator of RSA-Pace; has implanted more than 3,000 biventricular devices and led over 35 multi-centre trials. Awarded an OBE in the 2025 New Year Honours for services to heart failure.
Brenig Preest
More than 20 years in life-sciences finance across Europe and North America, with over £500M of investment as investor and adviser. Early career at Amersham / GE Healthcare and Coopers & Lybrand.
LinkedInBoard of directors
Chas Taylor
Serial cardiovascular-device entrepreneur who founded and exited three companies: MedNova, Novate and Veryan. Has raised more than £100M across the cycle. Joined Ceryx as Chairman in 2022.
LinkedIn
Professor Julian Paton
Director of the Centre for Heart Research (Manaaki Mānawa) at the University of Auckland, formerly the University of Bristol. The heart–lung synchronisation pacing concept originates from his laboratory, which led the preclinical work behind Cysoni.
LinkedIn
Dr Mark Strong
Former Vice President of R&D at Abbott, Boston Scientific and HeartWare, and former CEO of Heart Failure Solutions.
LinkedIn